hebei xiuna shangmao
We are professional supplier of xylazine tadanafil benzocaine lidocaine.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
| Product Name: | Lidocaine |
| Synonyms: | 2-(Diethylamino)-2',6'-acetoxylidide;2-(diethylamino)-2’,6’-acetoxylidide;2-(diethylamino)-n-(2,6-dimethylphenyl)-acetamid;2',6'-Acetoxylidide, 2-(diethylamino)-;6’-acetoxylidide,2-(diethylamino)-2;Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-;N-Di-ethylaminoacetyl-2,6-dimethylaniline;Lidocaine solution |
| CAS: | 137-58-6 |
| MF: | C14H22N2O |
| MW: | 234.34 |
| EINECS: | 205-302-8 |
| Product Categories: | Halogenated Heterocycles;Pharma materials;API;REGITINE;Other APIs;Alphacaine, Xylocaine, lignocaine;Research Chemical;137-58-6 |
| Mol File: | 137-58-6.mol |
| Lidocaine Chemical Properties |
| Melting point | 66-69°C |
| Boiling point | bp4 180-182°; bp2 159-160° |
| density | 0.9944 (rough estimate) |
| refractive index | 1.5110 (estimate) |
| Fp | 9℃ |
| storage temp. | Store at RT |
| solubility | ethanol: 4 mg/mL |
| form | powder |
| pka | pKa 7.88(H2O)(Approximate) |
| color | White to slightly yellow |
| Water Solubility | practically insoluble |
| Merck | 14,5482 |
| BCS Class | 1 |
| Stability: | Stable. Incompatible with strong oxidizing agents. |
| InChIKey | NNJVILVZKWQKPM-UHFFFAOYSA-N |
| LogP | 2.440 |
| CAS DataBase Reference | 137-58-6(CAS DataBase Reference) |
| NIST Chemistry Reference | Lidocaine(137-58-6) |
| EPA Substance Registry System | Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (137-58-6) |
| Safety Information |
| Hazard Codes | Xn,T,F |
| Risk Statements | 22-39/23/24/25-23/24/25-11 |
| Safety Statements | 22-26-36-45-36/37-16-7 |
| RIDADR | 3249 |
| WGK Germany | 3 |
| RTECS | AN7525000 |
| HazardClass | 6.1(b) |
| PackingGroup | III |
| HS Code | 29242990 |
| Hazardous Substances Data | 137-58-6(Hazardous Substances Data) |
| Toxicity | LD50 oral in rat: 317mg/kg |
| MSDS Information |
| Provider | Language |
|---|---|
| Xylocaine | English |
| Lidocaine Usage And Synthesis |
| description | Lidocaine is a local anesthetic, also known as Xylocaine, in recent years it has been replaced procaine, widely used in local infiltration anesthesia in cosmetic plastic surgery, it can block the nerve excitability and conduction by inhibiting the sodium channels of nerve cell membrane. The fat soluble and protein binding rate of lidocaine is higher than procaine, its cell penetrating ability is strong, fast onset, long duration of action, the interaction strength is 4 times of procaine. Lidocaine is used in infiltration anesthesia, epidural anesthesia, topical anesthesia (including thoracoscopy or abdominal surgery for mucosal anesthesia) and nerve block. In order to extend the time of anesthesia, reduce the poisoning of lidocaine and other side effects, can be added in the anesthetic epinephrine. Lidocaine can also be used for the treatment of ventricular premature beat after acute myocardial infarction, ventricular tachycardia, digitalis poisoning, cardiac surgery and cardiac catheterization-induced ventricular arrhythmias, including ventricular premature beats, ventricular tachycardia and ventricular fibrillation. Lidocaine is also used for duration status of epilepsy which other anti-seizure drugs are not effective, as well as local or spinal anesthesia. But it is usually ineffective for supraventricular arrhythmias. |
| Chemical property | Lidocaine is white needle like crystals, and its melting point is 68-69℃; boiling point is 180-182℃ (0.53kPa), soluble in ethanol in 159-160℃ (0.267kPa), ether, benzene, chloroform and oil, do not dissolve in water. In common use radical hydrochloride, lidocaine hydrochloride (C14H22N2O • HCL, [73-78-9]) is a white crystalline powder. Melting point 127-129℃, and the monohydrate melting point is 77-78℃. Easily soluble in water, 0.5% aqueous solution pHO 4.0-5.5. Odorless, bitter taste. |
| Uses | Lidocaine is an Anesthetic (local); antiarrhythmic (class IB). Long-acting, membrane stabilizing agent against ventricular arrhythmia. Originally developed as a local anesthetic. Neuroprotective & Neuroresearch Products. Lidocaine is widely used in surface anesthesia, anesthesia, conduction anesthesia and epidural anesthesia. The LD50 of oral lidocaine hydrochloride to mice was 290 mg/kg. |
| Description | Lidocaine [2-(diethylamino)-N-(2, 6-dimethylphenyl) acetamide monohydrochloride] is the most commonly used amino amide-type local anesthetic. Lidocaine is very lipid soluble and, thus, has a more rapid onset and a longer duration of action than most amino ester-type local anesthetics, such as procaine and tetracaine. It can be administered parenterally (with or without epinephrine) or topically either by itself or in combination with prilocaine or etidocaine as a eutectic mixture that is very popular with pediatric patients. The use of lidocaine–epinephrine mixtures should be avoided, however, in areas with limited vascular supply to prevent tissue necrosis. Lidocaine also frequently is used as a class IB antiarrhythmic agent for the treatment of ventricular arrhythmias, both because it binds and inhibits sodium channels in the cardiac muscle and because of its longer duration of action than amino ester-type local anesthetics. Central nervous system changes are the most frequently observed systemic toxicities of lidocaine. The initial manifestations are restlessness, vertigo, tinnitus, slurred speech, and eventually, seizures. Subsequent manifestations include CNS depression with a cessation of convulsions and the onset of unconsciousness and respiratory depression or cardiac arrest. This biphasic effect occurs because local anesthetics initially block the inhibitory GABAergic pathways, resulting in stimulation, and eventually block both inhibitory and excitatory pathways (i.e., block the sodium channels associated with the NMDA receptors, resulting in overall CNS inhibition). |
